Inhibition of SEMA3A in the prevention and treatment of ocular hyperpermeability

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9822367
SERIAL NO

14769255

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Described herein is a method of preventing or treating ocular vascular hyperpermeability including macular edema, in a subject comprising inhibiting Sema3A activity. Also disclosed are compositions and their use for preventing or treating Sema3A-dependent ocular vascular hyperpermeability.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
RSEM LIMITED PARTNERSHIPMONTRÉAL QUEBEC H3V 1H8

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Sapieha, Przemyslaw Montreal, CA 12 3

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 May 21, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 21, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00